NC
DNLI icon

NinePointTwo Capital’s Denali Therapeutics DNLI Stock Holding History

NinePointTwo Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,171
Closed -$404K – 209
2022
Q3 		$404K Buy
+13,171
New +$428K 0.16% 39

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

NinePointTwo Capital's DNLI Position: Q4 2022 in Review

NinePointTwo Capital sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 13,171 shares — an estimated $404K sold.

NinePointTwo Capital first reported a position in DNLI in Q3 2022 and held it in 1 quarter. The position peaked at $404K in Q3 2022. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • NinePointTwo Capital reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 13,171 Denali Therapeutics shares in Q4 2022, an estimated $404K.
  • NinePointTwo Capital first reported a position in Denali Therapeutics in Q3 2022 and held it in 1 quarter.
  • NinePointTwo Capital's Denali Therapeutics position peaked at $404K in Q3 2022.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on NinePointTwo Capital's 13F filing for Q4 2022, filed 14 Feb 2023.